These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35589944)

  • 21. Acute treatment patterns in patients with migraine newly initiating a triptan.
    Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptan medication use among patients with migraine with contraindications in the US.
    Pero A; Pace A; Dhamoon MS
    Headache; 2022 Jul; 62(7):883-889. PubMed ID: 35670141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
    Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Lee JH; Shewale AR; Barthold D; Devine B
    Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.
    Sacco S; Di Ciaccio S; Di Virgilio R; Pegoraro V; Ornello R
    Neurol Sci; 2024 Sep; 45(9):4427-4435. PubMed ID: 38538924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
    Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
    Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
    Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
    Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years.
    Piccinni C; Cevoli S; Ronconi G; Dondi L; Calabria S; Pedrini A; Esposito I; Favoni V; Pierangeli G; Cortelli P; Martini N
    J Headache Pain; 2019 Jun; 20(1):74. PubMed ID: 31248360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptan persistency among newly initiated users in a pharmacy claims database.
    Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
    Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of use and health expenses associated with triptans among adults with migraines.
    Wu J; Noxon V; Lu ZK
    Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms.
    Kogelman LJA; Falkenberg K; Ottosson F; Ernst M; Russo F; Stentoft-Hansen V; Demharter S; Tfelt-Hansen P; Cohen AS; Olesen J; Hansen TF
    Sci Rep; 2023 Jul; 13(1):12395. PubMed ID: 37524744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
    Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
    Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment persistence and switching in triptan users: a systematic literature review.
    Messali AJ; Yang M; Gillard P; Tsai K; Tepper SJ; Bloudek LM; Kori SH
    Headache; 2014; 54(7):1120-30. PubMed ID: 24912394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey.
    Nedergaard L; Martens MC; Christensen MDB; Pellesi L
    Pain Pract; 2024 Jul; 24(6):832-838. PubMed ID: 38450841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study.
    Wood ME; Lapane K; Frazier JA; Ystrom E; Mick EO; Nordeng H
    Paediatr Perinat Epidemiol; 2016 Mar; 30(2):190-200. PubMed ID: 26525300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.